Protective effect of evodiamine on zymosan-induced acute peritonitis in mice

Hao Chen; Xia Fan; Yu Sun; Jing Yu; Li Luo; Wanqi Tang; Wei Ma; Xue Yang; Huaping Liang; Jianping Gong

doi:10.16016/j.1000-5404.201608031

您当前的位置：

首页 >

文章列表页 >

Protective effect of evodiamine on zymosan-induced acute peritonitis in mice

Basic Medicin | 更新时间：2020-08-05

- Protective effect of evodiamine on zymosan-induced acute peritonitis in mice
- J Third Mil Med Univ Vol. 39, Issue 2, Pages: 163-168(2017)
- 作者机构：
  
  1.400010 重庆, 重庆医科大学附属第二医院肝胆外科
  2.400042 重庆, 第三军医大学大坪医院野战外科研究所第一研究室, 创伤、烧伤与复合伤国家重点实验室
- 作者简介：
- 基金信息：
  
  Supported by the General Program of National Natural Science Foundation of China(81372088)
- DOI：10.16016/j.1000-5404.201608031
  CLC： R284.1;R392.3;R572.2
- Published：30 January 2017，
  
  Received：5 August 2016，
  
  Accepted：6 October 2016
扫描看全文
Hao Chen, Xia Fan, Yu Sun, et al. Protective effect of evodiamine on zymosan-induced acute peritonitis in mice. [J]. J Third Mil Med Univ 39(2):163-168(2017)
DOI：

Hao Chen, Xia Fan, Yu Sun, et al. Protective effect of evodiamine on zymosan-induced acute peritonitis in mice. [J]. J Third Mil Med Univ 39(2):163-168(2017) DOI： 10.16016/j.1000-5404.201608031.

摘要

目的

探讨吴茱萸碱(evodiamine，EVO)对酵母多糖(zymosan，ZYM) 诱导的小鼠腹膜炎中炎症反应及中性粒细胞(polymorphonuclear neutrophil，PMN)浸润的影响。

方法

将54只成年雄性C57BL/6小鼠按随机数字表法分为正常对照组、模型组和EVO治疗组。模型组腹腔注射1 mg/mL ZYM溶液(1 mL)建立急性腹膜炎小鼠模型，EVO治疗组则同时腹腔注射10 mg/kg EVO及1 mg/mL ZYM溶液，正常对照组腹腔注射等量磷酸盐缓冲液。各组处理后2、6、12 h处死6只小鼠，收集眼眶血及腹腔灌洗液。采用酶联免疫吸附法检测血清及腹腔灌洗液中白介素6(interleukin-6

IL-6)、肿瘤坏死因子α(tumor necrosis factor-α

TNF-α)、角化细胞来源趋化因子(keratinocyte-derived chemokine

KC)及巨噬细胞炎性蛋白2(macrophage inflammatory protein 2

MIP-2)的含量；通过血细胞计数板计数腹腔灌洗液中混合细胞总数；利用流式细胞仪检测腹腔灌洗液中PMN比例及PMN中活性氧(reactive oxygen species，ROS)水平；采用Western blot检测6 h时腹腔灌洗液混合细胞中核转录因子-kB (nuclear factor-κB，NF-κB)p65入核情况。

结果

建模后2、6、12 h，模型组血清及腹腔灌洗液中IL-6、TNF-α、KC及MIP-2含量均高于正常对照组(

＜0.05)，EVO治疗组上述指标均较模型组明显降低(

＜0.05)，其中，血清中IL-6、KC及MIP-2均于2 h达高峰，随后逐渐下降，而TNF-α在2 h逐渐上升，6 h达到高峰，随后逐渐下降；腹腔灌洗液中TNF-α、KC及MIP-2均于2 h达高峰，随后逐渐下降，而IL-6在2 h逐渐上升，6 h达到高峰，随后逐渐下降。制模后6 h，EVO治疗组可显著降低腹腔混合细胞数与PMN数及其百分比(

＜0.05)，且PMN中ROS显著降低(

＜0.05)。另EVO治疗可显著降低腹腔混合细胞中细胞核的NF-κB p65表达(

＜0.05)。

结论

EVO可抑制ZYM诱导急性小鼠腹膜炎模型中血清及腹腔灌洗液中炎症因子及趋化因子的分泌，减轻腹腔PMN的浸润，并抑制PMN中ROS的产生，该作用可能是通过抑制NF-kB p65入核实现的。

Abstract

Objective

To determine the effect of evodiamine (EVO) on zymosan(ZYM)-induced acute peritonitis in mice and explore its mechanism.

Methods

Fifty-four adult male C57BL/6 mice were randomly divided into control group (phosphate buffer saline+10% dimethyl sulphoxide)

model group (ZYM 50 mg/kg +10% dimethyl sulphoxide)

and EVO treatment group (EVO 10 mg/kg+ZYM 50 mg/kg)

and the drugs were administered by intraperitoneal injection. Six mice in each group were sacrificed at 2

6 and 12 h respectively after the injection. Blood samples and peritoneal lavage fluid (PLF) were collected. The levels of interleukin-6 (IL-6)

tumor necrosis factor-α (TNF-α)

keratinocyte-derived chemokine (KC) and macrophage inflammatory protein 2 (MIP-2) in the serum and PLF were measured by enzyme linked immunosorbent assay (ELISA). The numbers of leukocytes and polymorphonuclear neutrophil (PMN) in PLF were determined by hemocytometry and flow cytometry

respectively. The level of reactive oxygen species (ROS) in PMN was also detected by flow cytometry. The protein expression of nuclear factor-κB p65 (NF-κB p65) in the leukocytes was analyzed by Western blotting.

Results

After ZYM injection

the levels of IL-6

TNF-α

KC and MIP-2 in the serum and PLF were significantly elevated at 2

6 and 12 h (

＜0.05)

while EVO treatment could dramatically reduce the levels of all the cytokines and chemokines (all

＜0.05). The serum levels of IL-6

KC and MIP-2 reached the peak in 2 h and then declined gradually. While that of TNF-α was elevated in 2 h and got the summit in 6 h

followed by slow reduction. The PLF levels of above cytokines and chemokines were in similiar trends as in the serum. Furthermore

EVO could notably reduce the numbers of ZYM-induced inflammatory cells and PMN in the PLF(

＜0.05)

and reduce the percentage of PMN and its ROS level at 6 h(

＜0.05). Western blot results showed that EVO treatment could down-regulate the NF-κB p65 expression in peritoneal inflammatory cells.

Conclusion

EVO can effectively alleviate ZYM-induced peritoneal inflammatory injury in the mice through reducing the secretion of cytokines and chemokines

inhibiting the infiltration of leukocytes and neutrophils

decreasing the percentage of neutrophils and ROS production

and down-regulating NF-κB p65 expression in the nuclei.

关键词

吴茱萸碱急性腹膜炎酵母多糖中性粒细胞浸润

Keywords

evodiamineacute peritonitiszymosanpolymorphonuclear neutrophil infiltration

references

Newson J, Stables M, Karra E, et al. Resolution of acute inflammation bridges the gap between innate and adaptive immunity[J]. Blood, 2014,124(11): 1748-1764.DOI: 10.1182/blood-2014-03-562710

Singer M, Deutschman C S, Seymour C W, et al. The third international consensus definitions for sepsis and septicshock (sepsis-3) [J]. JAMA, 2016, 315(8): 801-810. DOI: 10.1001/jama.2016.0287

Matsuda N, Takatani Y, Higashi T, et al. Severe infection in critical emergency care[J]. Nihon Rinsho, 2016, 74(2): 245-251.

Monroe L L, Armstrong M G, Zhang X, et al. Zymosan-induced peritonitis: effects on cardiac function, temperature regulation, translocation of bacteria and role of dectin-1[J]. Shock, 2016. [Epub ahead of print]. DOI: 10.1097/SHK.dsjydxxb-39-2-16300669

Talreja D, Singh P K, Kumar A. In vivo role of TLR2 and MyD88 signaling in eliciting innate immune responses in staphylococcal endophthalmitis[J]. Invest Ophthalmol Vis Sci, 2015, 56(3): 1719-1732. DOI: 10.1167/iovs.14-16087

Lerman Y V, Kim M. Neutrophil migration under normal and sepsis conditions[J]. Cardiovasc Hematol Disord Drug Targets, 2015, 15(1): 19-28.

Cash J L, White G E, Greaves D R. Chapter 17. Zymosan-induced peritonitis as a simple experimental system for the study of inflammation[J]. Methods Enzymol,2009,461: 379-396. DOI: 10.1016/S0076-6879(09)05417-2

Kobayashi Y. Effects of evodiamine, a major alkaloid of Goshuyu (Evodia Fruits), on TRPV1[J]. Nihon Yakurigaku Zasshi, 2015,146(3): 135-139. DOI: 10.1254/fpj.146.135

Hu C, Gao X, Han Y, et al. Evodiamine sensitizes BGC-823 gastric cancer cells to radiotherapy in vitro and in vivo[J]. Mol Med Rep,2016,14(1): 413-419. DOI: 10.3892/mmr.2016.5237

Chen T C, Chien C C, Wu M S, et al. Evodiamine from Evodia rutaecarpa induces apoptosis via activation of JNK and PERK in human ovarian cancer cells[J]. Phytomedicine, 2016, 23(1): 68-78. DOI: 10.1016/j.phymed.2015.12.003

Gavaraskar K, Dhulap S, Hirwani R R. Therapeutic and cosmetic applications of Evodiamine and its derivatives—A patent review[J]. Fitoterapia, 2015,106: 22-35. DOI: 10.1016/j.fitote.2015.07.019

Takada Y, Kobayashi Y, Aggarwal B B. Evodiamine abolishes constitutive and inducible NF-kappaB activation by inhibiting IkappaBalpha kinase activation, thereby suppressing NF-kappaB-regulated antiapoptotic and metastatic gene expression, up-regulating apoptosis, and inhibiting invasion[J]. J Biol Chem, 2005, 280(17): 17203-17212.DOI: 10.1074/jbc.M500077200

Liu Y N, Pan S L, Liao C H, et al. Evodiamine represses hypoxia-induced inflammatory proteins expression and hypoxia-inducible factor 1alpha accumulation in RAW264.7[J]. Shock, 2009, 32(3): 263-269.DOI: 10.1097/SHK.0b013e31819940cb

Lv Q, Xue Y, Li G, et al. Beneficial effects of evodiamine on P2X(4)-mediated inflammatory injury of human umbilical vein endothelial cells due to high glucose[J]. Int Immunopharmacol, 2015, 28(2): 1044-1049. DOI: 10.1016/j.intimp.2015.08.020

Hu Y, Mao A, Yu Z, et al. Anti-endotoxin and anti-inflammatory effects of Chinese herbal medicinal alkaloid ingredients in vivo[J]. Microb Pathog, 2016, 99: 51-55.DOI: 10.1016/j.micpath.2016.08.006

Ren X, Wang L, Wu X. A potential link between TSLP/TSLPR/STAT5 and TLR2/MyD88/NFκB-p65 in human corneal epithelial cells for Aspergillus fumigatus tolerance[J]. Mol Immunol, 2016, 71: 98-106. DOI: 10.1016/j.molimm.2015.12.014

Rosas E C, Correa L B, Pádua T A, et al. Anti-inflammatory effect of Schinus terebinthifolius Raddi hydroalcoholic extract on neutrophil migration in zymosan-induced arthritis[J]. J Ethnopharmacol, 2015, 175: 490-498. DOI: 10.1016/j.jep.2015.10.014

Lai X, Huang X, Zeng Y. Protective effect of anhydroicaritin against peritonitis in mice[J]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2013, 29(10): 1036-1039.

Zhang T Z, Yang S H, Yao J F, et al. Sangxingtang inhibits the inflammation of LPS-induced acute lung injury in mice by down-regulating the MAPK/NF-κB pathway[J]. Chin J Nat Med, 2015,13(12): 889-895. DOI: 10.1016/S1875-5364(15)30094-7

Hung N D, Kim M R, Sok D E. Mechanisms for anti-inflammatory effects of 1-[15(S)-hydroxyeicosapentaenoyl] lysophosphatidylcholine, administered intraperitoneally, in zymosan A-induced peritonitis[J]. Br J Pharmacol, 2011, 162(5): 1119-1135. DOI: 10.1111/j.1476-5381.2010.01117.x

Kovach M A, Standiford T J. The function of neutrophils in sepsis[J]. Curr Opin Infect Dis, 2012, 25(3): 321-327. DOI: 10.1097/QCO.0b013e3283528c9b

Su Y, Richmond A. Chemokine Regulation of Neutrophil Infiltration of Skin Wounds[J]. Adv Wound Care (New Rochelle), 2015, 4(11): 631-640. DOI: 10.1089/wound.2014.0559

Watzlawick R, Kenngott E E, Liu F D, et al. Anti-Inflammatory Effects of IL-27 in Zymosan-Induced Peritonitis: Inhibition of Neutrophil Recruitment Partially Explained by Impaired Mobilization from Bone Marrow and Reduced Chemokine Levels[J]. PLoS One, 2015, 10(9): e0137651. DOI: 10.1371/journal.pone.0137651.eCollection2015

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Anti-tumor mechanism of evodiamine on gastric cancer cells in vitro through MAPK signaling pathway

Antitumor activity of 2 new evodiamine derivatives against small-cell lung cancer cells in vitro

Evodiamine inhibits migration and invasion of colorectal cancer SW480 cells via suppressing NF-κB-p65 signaling pathway

PI3K/Akt信号与吴茱萸碱抑制人结肠癌细胞增殖的关系研究

吴茱萸碱抑制PI3K/AKT通路诱导小细胞肺癌H1688和H446细胞凋亡

Related Author

XIAO Haijuan

JIANG Yina

FANG Yu

LI Zhi

QIAN Weina

JIANG Xuejun

YANG Jianbo

ZENG Mei

Related Institution

Department of Oncology, Affiliated Hospital, 2School of Pharmacy, 3School of Basic Medicine, Shaanxi University of Traditional Chinese Medicine

Chongqing Key Laboratory of Biochemistry and Molecular Pharmacology,College of Pharmacy,Chongqing Medical University

Chongqing Collegiate Pharmaceutical Engineering Research Center,College of Pharmacy,Chongqing Medical University

Laboratory of Stem Cell and Tissue Engineering,Department of Histology and Embryology,College of Basic Medicine,Chongqing Medical University

College of Public Health and Management,Department of Histology and Embryology,College of Basic Medicine,Chongqing Medical University

⁰